Compare Trump Media and Technology Group Corp (DJT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs Merck & Co., Inc. — how do they compare? Trump Media and Technology Group Corp trades at $9.53 (market cap $2.50B), while Merck & Co., Inc. trades at $123.63 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 119.3× Trump Media and Technology Group Corp's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals.
| DJT | MRK | |
|---|---|---|
Market Cap | $2.50B | $298.31B |
Sector | Media | Health |
52-Week High | $19.86 | $129.52 |
52-Week Low | $7.06 | $77.60 |
Enterprise Value | $2.45B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.52, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported minimal revenue of $3.68M in 2025 alongside a massive net loss of -$712.06M, reflecting severe profitability challenges. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of a Truth Social spin-off, while a merger with TAE Technologies aims to pivot toward nuclear fusion energy.
The outlook remains highly speculative, with the stock's meme-driven volatility and fundamental weaknesses posing significant risks. Investment opportunity hinges on successful execution of the TAE merger and fusion technology prospects, but persistent losses and high valuation ratios suggest substantial downside potential if growth fails to materialize.
Merck (MRK) trades at $123.52, down 0.41% on the day, amid a bullish technical signal and strong institutional interest. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Valuation ratios include a P/E of 34.02 and P/S of 4.58, while cash flow from operations remains healthy at $16.47B in 2025.
The outlook for MRK is positive, driven by earnings beats, a dominant oncology portfolio, and analyst consensus favoring buys. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06 in 2025, and competitive pressures in the pharmaceutical sector. The stock offers potential upside to the consensus price target of $137.30, but investors should monitor execution risks from recent acquisitions and macroeconomic factors affecting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
